Signature Diagnostics Appoints Rainer Kramer to Chief Business Officer and Member of the Management Board
(Thomson Reuters ONE) -
Signature Diagnostics / Signature Diagnostics Appoints Rainer Kramer to Chief Business Officer and Member of the Management Board processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Potsdam, Germany, September 30, 2010 - Signature Diagnostics AG announced today
the appointment of Rainer Kramer as Chief Business Officer. Dr. Kramer
previously held the position of Vice President Corporate Business Development at
Jerini AG, where he was responsible for all licensing, partnering, and alliance
management activities. Before joining Jerini, he performed various research and
business development functions at MorphoSys AG, Martinsried, and Amgen Inc.,
Thousand Oaks.
"We are delighted to bring Rainer on board to help us exploit the enormous
potential of Signature's pioneering and best-in-class products for early
detection and prognosis of colorectal cancer," said André Rosenthal, CEO of
Signature. "Signature will launch its first products in early 2011 in certain EU
markets, either alone or with commercial partners, and Rainer's business savvy
and deal-making experience make him ideal to help lead Signature forward in this
pivotal next stage."
"I'm very excited to work with Signature's dynamic team to introduce innovative
tests that may change the face of detecting colorectal cancer," stated Dr.
Kramer. "The potential of these products to significantly improve both the
diagnosis and prognosis of one of the most common cancers worldwide is
far-reaching. By bringing CRC screening to a new level of accuracy and
sensitivity, these tests can detect cancer when it is still curable, thereby
improving survival rate."
Dr. Kramer holds a Diploma in Molecular Biology and a Ph.D from the
Max-Planck-Institute for Neurobiology. Throughout his career in corporate
business development, he contributed or delivered numerous strategic
partnerships and license deals encompassing technology platform and product
deals as well as equity transactions with an aggregate value of several hundred
million Euros. As a member of Jerini's M&A committee, he was instrumental in
the sale of Jerini to Shire in 2008 and was Shire's appointed principal for the
sale of JPT GmbH in 2009.
About Signature Diagnostics AG
Signature Diagnostics is a molecular oncology diagnostics company based in
Potsdam, Germany, focusing on the development and commercialization of
innovative and proprietary diagnostic products for the prognosis and early
detection/screening of colorectal cancer. Signature Diagnostics sponsors and
conducts large prospective, multicenter clinical trials with more than 25
primary care hospitals and several dozen colonoscopy centers in Germany to
discover and validate biomarkers for early detection/screening and prognosis of
colorectal and other cancers. The company's first products, Predictor C and
Detector C, will be launched in early 2011 in its own ISO15189 certified service
laboratory. For more information about Signature Diagnostics' colorectal cancer
tests, please visithttp://www.signature-diagnostics.de/.
[HUG#1448035]
--- End of Message ---
Signature Diagnostics
Hermannswerder 20 A Potsdam Germany
Press release (PDF):
http://hugin.info/143237/R/1448035/390470.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 30.09.2010 - 15:08 Uhr
Sprache: Deutsch
News-ID 43568
Anzahl Zeichen: 0
contact information:
Town:
Potsdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 453 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Signature Diagnostics Appoints Rainer Kramer to Chief Business Officer and Member of the Management Board"
steht unter der journalistisch-redaktionellen Verantwortung von
Signature Diagnostics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
